Results 1 to 10 of about 8,219 (198)

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study [PDF]

RMD Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab through 7 years in the ongoing SELECT-COMPARE study.Methods Patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) were randomised to placebo ...
Filip van den Bosch, Roy Fleischmann, Patrick Durez, Yoshiya Tanaka, Charles Peterfy, Ricardo Blanco, Eduardo Mysler, Louis Bessette, Jerzy Swierkot, Sebastian Meerwein, Diane Caballero, Duke Geem, Lingfeng Luo, Lauren D Smith   +13 more
doaj   +2 more sources

Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients

RMD Open
Objectives To evaluate the effectiveness and safety of upadacitinib in treatment-refractory inflammatory myositis.Methods Patients with refractory inflammatory myositis treated with upadacitinib from a single urban centre in Vancouver, British Columbia ...
Kun Huang, Jan Dutz, Madelaine Beckett
doaj   +2 more sources

Systematic analysis of adverse reaction signals induced by leflunomide, upadacitinib, and baricitinib in the treatment of rheumatoid arthritis: a FAERS database analysis [PDF]

Frontiers in Medicine
PurposeRheumatoid arthritis (RA) is a widely recognized chronic inflammatory disease. Leflunomide, upadacitinib, and baricitinib are frequently used to treat inflammatory diseases, including RA, although understanding of their associated adverse drug ...
Jizheng Dang, Li Shu
doaj   +2 more sources

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Heliyon, 2023
Background: The sparsity of head-to-head trials for medications used as in atopic dermatitis (AD) treatment makes therapy options difficult. Objective: To better compare the efficacy and safety of abrocitinib and upadacitinib with dupilumab in patients ...
Qin Gao, Yanxia Zhao, Junling Zhang
doaj   +1 more source

Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study

Dermatology and Therapy, 2023
Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib.
Nobukazu Hayashi, Masanori Ikeda, John Liu, Eliza Raymundo, Yingyi Liu, Takuya Sasaki, Kenshi Yamasaki   +6 more
doaj   +1 more source

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

RMD Open, 2022
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at week 14
Désirée van der Heijde, Filip van den Bosch, Atul Deodhar, Joachim Sieper, Bernard Combe, Walter P Maksymowych, In-Ho Song, Tae-Hwan Kim, Mitsumasa Kishimoto, Yuanyuan Duan, Yunxia Sui, Andrew J Östör, Peter K Wung   +12 more
doaj   +1 more source

Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan [PDF]

Intestinal Research
Background/Aims Tofacitinib and upadacitinib are small-molecule compounds that inhibit the Janus kinase pathway for the treatment of refractory ulcerative colitis.
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
doaj   +1 more source

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysisCapsule Summary

JAAD International, 2022
Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic ...
Norito Katoh, MD, PhD, Yukihiro Ohya, MD, PhD, Hiroyuki Murota, MD, PhD, Masanori Ikeda, MD, PhD, Xiaofei Hu, PhD, Kimitoshi Ikeda, PhD, John Liu, MD, MS, Takuya Sasaki, Alvina D. Chu, MD, Henrique D. Teixeira, PhD, MBA, Hidehisa Saeki, MD, PhD   +10 more
doaj   +1 more source

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation

Качественная клиническая практика, 2020
Aim. To assess the pharmacoeconomic feasibility of including the drug upadacitinib in restrictive lists and government funding programs to provide patients with rheumatoid arthritis.Materials and methods.
A. M. Lila, S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

RMD Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 mg once daily ...
Roy Fleischmann, Patrick Durez, Eduardo Mysler, Louis Bessette, Yihan Li, Nasser Khan, Charles G Peterfy, Jerzy Swierkot, Xianwei Bu, Sara K Penn   +9 more
doaj   +1 more source